Vaccination updates and special considerations for systemic lupus erythematosus patients.
Curr Opin Rheumatol
; 36(2): 148-153, 2024 Mar 01.
Article
em En
| MEDLINE
| ID: mdl-37976046
PURPOSE OF REVIEW: We review the latest guidelines and note special considerations for systemic lupus erythematosus (SLE) patients when approaching vaccination against SARS-CoV-2, influenza, pneumococcus, herpes zoster, and potentially respiratory syncytial virus (RSV) vaccine in the future. RECENT FINDINGS: SLE patients have unique infectious risks due to newer treatments and the nature of the disease itself. It is important to balance the benefit of additional protective immunity from updated vaccines against the possible risk of disease activity exacerbations. SUMMARY: It is important to continuously evaluate the safety and immunogenicity of updated vaccines specifically for SLE patients. Additionally, the newly approved RSV vaccine should be considered for this population to reduce severe respiratory illness.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Vacinação
/
Lúpus Eritematoso Sistêmico
Limite:
Humans
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article